{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T01:33:41Z","timestamp":1769823221787,"version":"3.49.0"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2022,8,23]],"date-time":"2022-08-23T00:00:00Z","timestamp":1661212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,8,23]],"date-time":"2022-08-23T00:00:00Z","timestamp":1661212800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Rheumatol"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1038\/s41584-022-00832-1","type":"journal-article","created":{"date-parts":[[2022,8,23]],"date-time":"2022-08-23T17:05:24Z","timestamp":1661274324000},"page":"557-558","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Sarcoidosis: can tofacitinib slay the dragon?"],"prefix":"10.1038","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2215-0221","authenticated-orcid":false,"given":"Nadera J.","family":"Sweiss","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Baughman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,8,23]]},"reference":[{"key":"832_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-30615-x","volume":"13","author":"W Damsky","year":"2022","unstructured":"Damsky, W. et al. Inhibition of type 1 immunity with tofacitinib is associated with marked improvement in longstanding sarcoidosis. Nat. Commun. 13, 3140 (2022).","journal-title":"Nat. Commun."},{"key":"832_CR2","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1097\/MCP.0000000000000809","volume":"27","author":"M Song","year":"2021","unstructured":"Song, M. et al. Sarcoidosis and autoimmunity. Curr. Opin. Pulm. Med. 27, 448\u2013454 (2021).","journal-title":"Curr. Opin. Pulm. Med."},{"key":"832_CR3","doi-asserted-by":"publisher","first-page":"2004079","DOI":"10.1183\/13993003.04079-2020","volume":"58","author":"RP Baughman","year":"2021","unstructured":"Baughman, R. P. et al. ERS clinical practice guidelines on treatment of sarcoidosis. Eur. Respir. J. 58, 2004079 (2021).","journal-title":"Eur. Respir. J."},{"key":"832_CR4","first-page":"49","volume":"27","author":"NJ Sweiss","year":"2010","unstructured":"Sweiss, N. J. et al. C-reactive protein predicts response to infliximab in patients with chronic sarcoidosis. Sarcoidosis Vasc. Diffuse Lung Dis. 27, 49\u201356 (2010).","journal-title":"Sarcoidosis Vasc. Diffuse Lung Dis."},{"key":"832_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.901437","author":"T Iwasaki","year":"2022","unstructured":"Iwasaki, T. et al. Dynamics of type I and type II interferon signature determines responsiveness to anti-TNF therapy in rheumatoid arthritis. Front. Immunol. https:\/\/doi.org\/10.3389\/fimmu.2022.901437 (2022).","journal-title":"Front. Immunol."},{"key":"832_CR6","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1056\/NEJMra2101555","volume":"385","author":"M Drent","year":"2021","unstructured":"Drent, M., Crouser, E. D. & Grunewald, J. Challenges of sarcoidosis and its management. N. Engl. J. Med. 385, 1018\u20131032 (2021).","journal-title":"N. Engl. J. Med."},{"key":"832_CR7","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1097\/MCP.0000000000000403","volume":"23","author":"JC Schupp","year":"2017","unstructured":"Schupp, J. C., Vukmirovic, M., Kaminski, N. & Prasse, A. Transcriptome profiles in sarcoidosis and their potential role in disease prediction. Curr. Opin. Pulm. Med. 23, 487\u2013492 (2017).","journal-title":"Curr. Opin. Pulm. Med."},{"key":"832_CR8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0029126","volume":"6","author":"NJ Sweiss","year":"2011","unstructured":"Sweiss, N. J. et al. Linkage of type I interferon activity and TNF-alpha levels in serum with sarcoidosis manifestations and ancestry. PLoS One 6, e29126 (2011).","journal-title":"PLoS One"},{"key":"832_CR9","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1164\/ajrccm.156.5.9506031","volume":"156","author":"CP Wyser","year":"1997","unstructured":"Wyser, C. P., van Schalkwyk, E. M., Alheit, B., Bardin, P. G. & Joubert, J. R. Treatment of progressive pulmonary sarcoidosis with cyclosporin A. A randomized controlled trial. Am. J. Respir. Crit. Care Med. 156, 1371\u20131376 (1997).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"832_CR10","first-page":"2129","volume":"34","author":"NJ Sweiss","year":"2007","unstructured":"Sweiss, N. J. & Baughman, R. P. Tumor necrosis factor inhibition in the treatment of refractory sarcoidosis: slaying the dragon? J. Rheumatol. 34, 2129\u20132131 (2007).","journal-title":"J. Rheumatol."}],"container-title":["Nature Reviews Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41584-022-00832-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41584-022-00832-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41584-022-00832-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,23]],"date-time":"2022-09-23T10:12:28Z","timestamp":1663927948000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41584-022-00832-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,23]]},"references-count":10,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["832"],"URL":"https:\/\/doi.org\/10.1038\/s41584-022-00832-1","relation":{},"ISSN":["1759-4790","1759-4804"],"issn-type":[{"value":"1759-4790","type":"print"},{"value":"1759-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,23]]},"assertion":[{"value":"23 August 2022","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}